PROCF (Sofgen Pharma) EBIT per Share: $0.87 (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROCF Sofgen Pharma SA PROCF
24 GF Score
Price $0.00
View Full Analysis

What is Sofgen Pharma EBIT per Share?

Sofgen Pharma PROCF 24 EBIT per Share is $0.87 as of Dec. 2024. GuruFocus rates PROCF with a GF Score™ of 24/100.

Sofgen Pharma's EBIT per Share for the three months ended in Dec. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.87.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sofgen Pharma's EBIT per Share or its related term are showing as below:

PROCF's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sofgen Pharma's EBIT for the three months ended in Dec. 2024 was $0.0 Mil.

Sofgen Pharma  (OTCPK:PROCF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sofgen Pharma EBIT per Share Related Terms

Sofgen Pharma EBIT per Share Historical Data

* Premium members only.

The historical data trend for Sofgen Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sofgen Pharma EBIT per Share Chart

Sofgen Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial 0.47 -0.09 0.73 0.86 -0.42

Sofgen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Dec24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.49 0.22 -0.02 0.00
PROCF
24GF Score
Sofgen Pharma SA PROCF
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sofgen Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sofgen Pharma's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-42.103/100.271
=-0.42

Sofgen Pharma's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

EBIT per Share(Q: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=0/100.271
=0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $0.87 mean?
Sofgen Pharma (PROCF) has a EBIT per Share of $0.87 as of Dec. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sofgen Pharma and its competitors.
Is Sofgen Pharma's EBIT per Share too high?
Sofgen Pharma's current EBIT per Share is $0.87. The Drug Manufacturers industry median EBIT per Share is 7.75. Sofgen Pharma's value of $0.87 is 88.8% below this industry median. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's EBIT per Share compare to BKUH and ORGO?
Sofgen Pharma's EBIT per Share of $0.87 can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.75. Sofgen Pharma's value of $0.87 is 88.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.75, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sofgen Pharma's current EBIT per Share of $0.87 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sofgen Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sofgen Pharma's current EBIT per Share is $0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PROCF) has a current EBIT per Share of $0.87. The current EBIT per Share is $0.87 and 88.8% below the Drug Manufacturers industry median of 7.75. Sofgen Pharma's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sofgen Pharma (PROCF), the current EBIT per Share is $0.87 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PROCF

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price